Article Per Year (5 Year)
p-Index From 2021 - 2026
1.745
P-Index
This Author published in this journals
All Journal Alchemy : Journal of Chemistry Indonesian Journal of Cancer Chemoprevention Majalah Obat Tradisional INDONESIAN JOURNAL OF PHARMACY Journal of Islamic Pharmacy Science and Technology Indonesia Jurnal Farmasi Sains dan Komunitas Journal of Islamic Medicine Pharmacology and Clinical Pharmacy Research Jurnal Tumbuhan Obat Indonesia
Roihatul Mutiah
Universitas Islam Negeri Maulana Malik Ibrahim Malang
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Energy Environmental Science Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Physics Public Health

Published : 24 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 24 Documents
Search

 1   2   3 
Compound Identification and Anticancer Activity of Ethyl Acetate Fraction from Bawang Sabrang (Eleutherine palmifolia (L.) Merr.) on HeLa Cervical Cancer Cell Line Mutiah, Roihatul; Minggarwati, Trian Sidha; Kristanti, Risma Aprinda; Susanti, Erna
Indonesian Journal of Cancer Chemoprevention Vol 10, No 3 (2019)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev10iss3pp131-139

Abstract

Eleutherine palmifolia (L.) Merr. is a typical plant found in Central Kalimantan that has been used empirically by the Dayak people as medicine for various diseases, including cancer. The plant contains flavonoid compounds that potentially used as an anticancer. The purpose of this study is to find the most active fraction, indicated by its cytotoxic potency on HeLa cervical cancer cell line, and to identify compounds in E. palmifolia bulbs fraction. E. palmifolia bulbs was extracted by maceration. The extraction with ultrasonic bath and partition fractionation was conducted by using n-hexane, chloroform, and ethyl acetate. Each fraction was tested for toxicity level on HeLa cells using MTT assay. The identification of active compounds was carried out by Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS). The result showed that based on the IC50 value, the ethyl acetate fraction had the highest bioactivity. IC50 values of n-hexane, chloroform, and ethyl acetate fractions were 250.77±19.01; 720.46±42.38; and 44.34±9.45μg/mL, respectively. The identification of the active compound in ethyl acetate fraction resulted 28 chemical compounds. Compounds with the highest percentage area were isoliquiritigenin and oxyresveratrol. The ethyl acetate fraction of E. palmifolia bulbs is potential to be developed as an anticancer candidate (phytopharmaceutical).Keywords: Compound identification, Anticancer activity, Eleutherine palmifolia (L.) Merr., cervical cancer
Induction of Helianthus annuus Leaves Extract to HeLa cell Apoptosis and Cell Cycle Arrest in S, G2-M and M5 Phase Mutiah, Roihatul; Ulfah, Jauza; Amrulloh, Muhammad Firman; Suryadinata, Arief; Indrawijaya, Yen Yen Ari; Rahmawati, Ana
Indonesian Journal of Cancer Chemoprevention Vol 13, No 1 (2022)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev13iss1pp1-11

Abstract

Helianthus annuus L. (H. annuus) is a potential medicinal plant for cancer therapy. The aims of this study is to identify profile the anticancer activity of H. annuus L. from its leaves, root, stem, and seed as well as to elucidate the apoptosis and cell cycle of the leaves. Ten-gram sample of the powder were extracted by using Ultrasound-Assisted Extraction (UAE) with 200 ml of 96% ethanol by comparison of 1:20 with three times replications. The determination of anticancer activity was used the MTT cell proliferation assay, while apoptosis test and cell cycle were applied with the flowcytometry test. The value of IC50 in 96% ethanol extract in the root and stem was >1,000 μg/mL; seed and leaves were 153.76 μg/mL; and 126.6 μg/mL, respectively. The apoptosis induction of H. annuus leaves extract treatment was 7.17% of apoptosis cells; 90.44% of necrosis, and 2.39% of living cells. The H. annuus leaves extract also significantly caused a decrease of cell percentage in G0-G1 phase (p<0.001) and an increase in G2-M phase (p<0.001). The H. annuus leaves extract had greater potential as anticancer instead of other parts. The adding of H. annuus leaves extract increased the HeLa cell apoptosis, decreased percentage of HeLa cells in G0-G1 phase, and increased percentage of HeLa cells in G2-M phase. Cell cycle mechanism test showed cell cycle arrest in S, G2-M, and M5 phase in 24 h, hence inhibited the mitosis process.Keywords: anticancer, Helianthus annuus L, apoptosis, cell cycle.
Secondary Metabolites Analysis and Anti-Cancer Potential of Lansium parasiticum Extract Mutiah, Roihatul; Safina, Nilna Amalia Nur; Briliana, Malich Septi Diajeng
Majalah Obat Tradisional Vol 31, No 1 (2026)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/mot.99979

Abstract

Cancer is a non-communicable disease characterized by uncontrolled growth of malignant cells. The leaves and stems of Lansium parasiticum have been recognized for their potential as an anti-cancer agent. However, research reporting secondary metabolite profiles and anti-cancer activity in these plants remains limited. This study aimed to identify compounds, compare compound profiles, and predict the anti-cancer activity of secondary metabolites present in the leaves and stem bark of Lansium parasiticum. The secondary metabolite profile was analyzed using UPLC-MS/MS (Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry) chromatogram data interpretation, while the prediction of anticancer activity was made by referencing the Probability Activity value obtained through the PASS (Prediction of Activity Spectra for Substances) Server. The results revealed 24 bioactive compounds successfully identified from the Lansium parasiticum leaf extract, with Emindole Sb as the major compound comprising 19.3% of the total chromatographic area. Meanwhile, the analysis identified 23 bioactive compounds in the stem bark extract of Lansium parasiticum, with Moronic Acid as the major constituent, representing 14.29% of the total chromatographic area. The examination of the anticancer potential utilizing a probability activity method suggests that both the leaves and stem bark of Lansium parasiticum demonstrate antineoplastic, chemopreventive, and apoptosis-inducing activities.
Anticancer Synergy of Myricetin and Doxorubicin in Breast Cancer: Network Pharmacology and In Vitro Evaluation Mutiah, Roihatul; Ma'arif, Burhan; Inayah, Indah Rahmatul; Fitrianingsih, Avin Ainur
Majalah Obat Tradisional Vol 31, No 1 (2026)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/mot.103080

Abstract

Breast cancer is a major public health problem worldwide, leading to an urgent need for the development of new strategies to improve treatment efficacy and manage drug resistance. Doxorubicin is among the most commonly used chemotherapy drugs and has the disadvantage of being easy resistance and toxicity, which causes limited efficiency. A potentially effective strategy is combining doxorubicin with natural compounds possessing anticancer activity and the ability to modulate drug resistance pathways. Therefore, this study aimed to explore the potential of combining myricetin and doxorubicin as an effective and safe anticancer treatment. A network pharmacology method was used to examine how the two compounds interact at the molecular level, including the target genes, signaling pathways, and possible synergistic effect. Additionally, laboratory (in vitro) tests were performed using MTT assay to evaluate the toxicity of the compounds to both T47D breast cancer and normal Vero cells. Several key parameters, including IC50 values of each compound, as well as the combination index and selectivity index (SI), were analyzed to evaluate the safety against normal cells. The results showed that the combination of myricetin and doxorubicin targeted 19 interconnected genes triggering apoptosis often associated with cancer treatment. Laboratory tests (in vitro) found that myricetin and doxorubicin had moderate anticancer or cytotoxic activity, with IC50 values of 31.936 µg/mL and 27.39 µg/mL, respectively. The combination at concentrations of 7.984 µg/mL myricetin + 3.424 µg/mL doxorubicin, 15.986 µg/mL myricetin + 3.424 µg/mL doxorubicin, and 31.936 µg/mL myricetin + 3.424 µg/mL doxorubicin had a powerful synergistic effect as well as high viability in Vero cells with a value of 168.756 µg/mL. Based on the determined combination concentrations and IC50 values of the compounds, myricetin, and doxorubicin showed potential synergistic activity against breast cancer cells. Breast cancer remains a significant global health challenge, necessitating the development of novel strategies to enhance treatment efficacy and combat drug resistance. Doxorubicin, a common chemotherapeutic drug, has limitations owing to its resistance and toxicity. This study investigated the potential of combining myricetin, a natural compound, with doxorubicin to address these issues. Employing a network pharmacology approach, we first explored the molecular interactions between myricetin and doxorubicin and identified target genes, signaling pathways, and potential synergistic effects. Concurrently, in vitro experiments using the MTT assay assessed the toxicity of the compounds in T47D breast cancer cells and normal Vero cells. The key parameters analyzed included the IC50 values, combination index, and selectivity index to evaluate safety. Our findings revealed that the combination of myricetin and doxorubicin targeted 19 interconnected genes that are frequently associated with apoptosis during cancer treatment. In vitro tests showed that both myricetin and doxorubicin exhibited moderate cytotoxic activity, with IC50 values of 31.936 µg/mL and 27.39 µg/mL, respectively. Specific combinations (e.g., 7.984 µg/mL myricetin + 3.424 µg/mL doxorubicin) demonstrated a powerful synergistic effect against breast cancer cells, while maintaining high viability in normal Vero cells (168.756 µg/mL). These results suggested that the combination of myricetin and doxorubicin offers a promising synergistic approach for breast cancer treatment.
Co-Authors Abdul Hakim Ach. Nashichuddin Ahmad, Ananda Rizkia Azizah Amrulloh, Muhammad Firman Andiartama, Amanda Milano Anik Listiyana Anik Listyana Annisa, Rahmi Arief Suryadinata Aty Widyawaruyanti Avin Ainur Fitrianingsih Begum Fauziyah Briliana, Malich Septi Diajeng Dhani Wijaya, Dhani Elok Kamilah Hayati Erna Susanti Fathia Faza Rahmadanita Ferry Sandra Habibah, Atiqoh Nur Hadya, Chorida Muhjatul Hariz, Muhammad Fawaz Huwaida, Fadhila Isma Inayah, Indah Rahmatul Indradewa, Rhian Irawati, Santia Janaloka, Nandana Adyuta Kirana, Farenza Okta Laily Nurul Azizah Lestari, Nia Ayu Ma'arif Z.A, Burhan Ma'arif, Burhan Ma'arif, Burhan Minggarwati, Trian Sidha Muhammad Zainuddin Mustofa, Muhammad Ragib Nafisah, Fika Sayyidatun Nurlaili Susanti Octavia, Nur Ika Purwaningsih, Fauziyah Eni Qonita, Kesimira Rahmi Annisa Ramadhani D.A., Ria Retno Susilowati Ria Ramadhani Dwi Atmaja Risma Aprinda Kristanti Sadli Syarifuddin Safina, Nilna Amalia Nur Salsabila, Dhia Fadhilah Salsabilla, Farida Rahma Samah, Moh.Alfin Siti Zulaikah Sukardiman Sukma, Yolanda Cahyaning Suyadinata, Arief Tanaya Jati Dharma Dewi Taufik, Imam Ulfah, Jauza Weka Sidha Bhagawan Wirda Anggraini Yen Yen Ari Indrawijaya Zahiro, Syayida Roisatus